Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2127399 in Methotrexate-Inadequate Response Rheumatoid Arthritis
2010-022205-17Phase 3Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tabalumab in rheumatoid arthritis (RA) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: ACR20 response at Week 24. Started Dec 2010; status: terminated.
02
Drugs
tabalumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2010-022205-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022205-17.